Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: Development and evaluation of a new nomogram

Author:

Zheng Xiaoxia1,Ye Jiangnan2,Zhan Qunzhang1,Zhao Weifeng3,Liao Zhongqin1,Ye Xiaolin1,Qu Chongzheng3

Affiliation:

1. Guangzhou University of Chinese Medicine

2. Chengdu University of Traditional Chinese Medicine

3. The Third Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Abstract

Abstract Objective: To construct a new prediction nomogram to predict the risk of musculoskeletal pain in patients with primary osteoporosis who receive zoledronic acid intravenously for the first time. Method: Clinical data of 368 patients with primary osteoporosis who received the first intravenous injection of zoledronic acid in our hospital from December 2019 to December 2022 were studied. Patients were divided into a musculoskeletal pain group (n =258) and a non-musculoskeletal pain group (n =110) based on the presence or absence of musculoskeletal pain 3 days after injection. Statistically significant predictors were screened by logistic regression analysis and the minimum absolute contraction and selection operator (LASSO) to construct a nomogram. The nomogram was evaluated by the receiver operating characteristic (ROC) curve, the calibration curve, the C-index, and the decision curve analysis (DCA) and verified in a validation cohort. Results: The independent predictors of the nomogram were age, serum 25-hydroxyvitamin D, NSAIDs, vitamin D, and BMI. The area under the ROC curve (AUC) was 0.980 (95% CI, 0.915–0.987), showing excellent predictive performance. The nomogram c index was 0.980, and the nomogram c index for internal verification remained high at 0.979. Moreover, calibration curves show that the nomogram has good consistency. Finally, the DCA showed that the net benefit of the nomogram was 0.20-0.49. Conclusion: Establish an accurate and reliable nomogram for musculoskeletal pain after the first intravenous administration of zoledronic acid. Clinicians must pay attention to the evaluation and prevention of adverse reactions after zoledronic acid injection in order to increase patients' willingness to receive a second dose of zoledronic acid.

Publisher

Research Square Platform LLC

Reference27 articles.

1. Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study [J];WANG L;JAMA Netw open,2021

2. MOHD-TAHIR N A, LI SC. Economic burden of osteoporosis-related hip fracture in Asia: a systematic review [J]. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, 28(7): 2035-44.

3. Prevalence of osteoporosis in China: a meta-analysis and systematic review [J];CHEN P;BMC Public Health,2016

4. Clinical Practice. Postmenopausal Osteoporosis [J];BLACK D M ROSENCJ;N Engl J Med,2016

5. Fracture risk and zoledronic acid therapy in men with osteoporosis [J];BOONEN S;N Engl J Med,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3